Flu season visitor restriction – age 16 or older (Restricción de visitantes durante la Temporada de Influenza (Flu) – Mayores de 16 años.)

Flu Season Visitor Restriction

Visitors temporarily restricted to age 16 or older

As a safety first organization, Christiana Care is implementing a temporary visitation age restriction starting Friday, Jan. 18. This temporary restriction protects patients, their loved ones and health care workers during this time of extremely high number of influenza cases and other respiratory illnesses circulating in our community.

The new restrictions limit visitors to patients in Christiana and Wilmington hospitals to persons age 16 or older. Children and teens younger than 16 years are most likely to get the flu and remain contagious longer than adults. This restriction does not apply to outpatient and ambulatory services. We began restricting visitors under the age of 16 years in our Neonatal Intensive Care Unit (NICU) and Women’s and Children’s areas on Jan. 18.

Thank you for your understanding and cooperation.

For more information about the Flu visit our Health Library.


Restricción de visitantes durante la Temporada de Influenza (Flu)

Temporalmente solo se permiten los visitantes mayores de 16 años.

Como una organización que promueve la seguridad ante todo, Christiana Care está implementando una restricción temporal en la edad de visitantes a partir del viernes 18 de enero. Esta restricción temporal protege a los pacientes, a sus seres queridos y al personal de cuidados de salud durante esta época con un número extremadamente alto de casos de influenza y de otras enfermedades respiratorias que circulan en nuestra comunidad.

Las nuevas restricciones, en los hospitales Christiana y Wilmington, sólo permiten visitas a pacientes de personas mayores de 16 años. Los niños y adolescentes menores de 16 años son más propensos a contraer el flu y son contagiosos por más tiempo que los adultos. Esta restricción no aplica a las áreas de servicios ambulatorios. Comenzamos la restricción de visitas a menores de 16 años en nuestra Unidad de Cuidados Intensivos Neonatales (NICU) y en las áreas para Mujeres y Niños desde el 18 de enero.

Gracias por su comprensión y cooperación.

Para más información sobre la gripe, visite nuestra Biblioteca de Salud.

Cancer Research at the
Helen F. Graham Cancer Center
& Research Institute

Colon Cancer Research

Program Description

The long term goal of the research led by Bruce Boman, M.D., Ph.D., is to identify cancer stem cell-based targets that will lead to the development of new more effective, potentially even curative, treatments for patients with advanced colorectal cancer.

Based on the emerging paradigm in oncology, effective treatments will need to target cancer stem cells, which are the cells that become overpopulated during tumorigenesis and drive tumor growth. To understand how stem cell overpopulation drives tumor growth, Dr. Boman’s lab has been studying the effect of the main mutation (i.e. APC) that drives the development of colorectal cancer. APC mutations are the most frequent (>85%) genetic alteration occurring in colorectal cancers. Dr. Boman’s lab found that APC mutations cause progressive expansion of the SC population during development of colorectal cancer in humans. This finding led to the publication that stem cell overproduction results from increased symmetric stem cell division.

Dr. Boman’s lab recently discovered that ALDH is a marker for colonic stem cells, and allows the tracking of stem cell overpopulation due to APC mutation during colon cancer development. This recent discovery raised the question: What are the underlying mechanisms that lead to stem cell overpopulation? To seek an answer, Dr. Boman’s lab is currently investigating which ALDH isoforms are critical to ALDH activity, whether specific pathways, such as neuroendocrine or retinoid, are involved in maturation and death of cancer stem cells, and what kinetic mechanisms drive colon cancer growth and development. Based on their research findings, the lab’s scientific team postulates that targeting the cellular mechanisms affected by APC mutation that cause cancer stem cell overpopulation and drive colon tumor growth offers a new and more effective approach toward treatment of colorectal cancer.

Overall, the research findings by this team of scientists at the Center for Translational Cancer Research provide new concepts on how discoveries from basic cancer research might be translated into the clinical setting with the development of new therapies for patients with advanced stages of colorectal cancer.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.